Bioclinica, Inc. (BIOC) Tops Q4 EPS by 2c, Sales Beat Expectations

Bioclinica, Inc. (NASDAQ: BIOC) reported Q4 EPS of $0.09, $0.02 better than the analyst estimate of $0.07. Revenue for the quarter came in at $22.57 million versus the consensus estimate of $20.84 million.

For earnings history and earnings-related data on Bioclinica, Inc. (BIOC) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• H&R Block (HRB) Tops Q4 EPS by 7c, Offers Guidance
• RideNow Group, Inc. (RDNW) Tops Q2 EPS by 4c
• Pliant Therapeutics, Inc. (PLRX) Misses Q2 EPS by 2c